Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211)
Market Closed
11 Aug, 06:57
XSHE XSHE Primary ¥
11. 69
+0.1
+0.8628%
¥
6.34B Market Cap
- P/E Ratio
0.34% Div Yield
11.39M Volume
- Eps
¥ 11.59
Previous Close Want to track 301211 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
301211 closed today higher at ¥11.69, an increase of 0.8628% from yesterday's close, completing a monthly increase of 3.2686% or ¥0.37. Over the past 12 months, 301211 stock lost -4.4935%.
301211 pays dividends to its shareholders, with the most recent payment made on Jun 12, 2026. The next estimated payment will be in In 10 months on Jun 12, 2027 for a total of ¥0.06.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. has completed 2 stock splits, with the recent split occurring on Aug 27, 2025.
The company's stock is traded on one exchange.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211) FAQ
What is the stock price today?
The current price is ¥11.69.
On which exchange is it traded?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 301211.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.34%.
What is its market cap?
As of today, the market cap is 6.34B.
Has Hubei Biocause Heilen Pharmaceutical Co., Ltd. ever had a stock split?
Hubei Biocause Heilen Pharmaceutical Co., Ltd. had 2 splits and the recent split was on Aug 27, 2025.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Profile
| Insurance Industry | Financials Sector | Ms. Wenxia Zhou CEO | XSHE Exchange | CNE100005782 ISIN |
| CN Country | 1,765 Employees | 12 Jun 2026 Last Dividend | 27 Aug 2025 Last Split | 12 Nov 1996 IPO Date |
Overview
Hubei Biocause Pharmaceutical Co., Ltd. is a multifaceted enterprise based in Jingmen, China, with a primary focus on providing life and motor insurance products to the Chinese market. Beyond insurance, the company has diversified interests in the pharmaceutical, chemical, and new energy fuel sectors. The firm is engaged in both research and production activities across a variety of products and services. With an international footprint, Hubei Biocause Pharmaceutical exports its products to approximately 85 countries worldwide, including the United States and the European Union, showcasing its global reach and the diverse markets it serves.
Products and Services
- Life and Motor Insurance: Offering comprehensive insurance solutions tailored to meet the needs of individuals and families in China, the company provides essential financial protection against life's uncertainties.
- Pharmaceuticals: The company is actively involved in contract research and the production of APIs (Active Pharmaceutical Ingredients), intermediates, and various formulations such as tablets, granules, and capsules. These pharmaceutical products are designed to meet rigorous health and safety standards, addressing different therapeutic needs.
- Chemicals: Hubei Biocause Pharmaceutical provides a range of chemicals for industrial applications. This includes the manufacture of dimethyl ether gas, used as an aerosol propellant or a liquefied gas fuel, and a-chloropropionyl chloride, a key intermediate in organic synthesis.
- New Energy Fuels: In line with global sustainability efforts, the company invests in the new energy fuel sector, focusing on the development and production of cleaner, more efficient fuel alternatives to traditional fossil fuels.
Contact Information
Address: 122-132 Yangwan Road, Jingmen, China, 448000
Phone: 86 27 6565 1730
Website: https://www.biocause.com/
